990P - ERCC1 expression as predictive biomarker for platinum containing chemotherapy regimens in ovarian carcinoma

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Ovarian Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Mehmet Ulker
Authors M. Ulker1, B.B. Duman2, B. Sahin3, D. Gumurdulu4
  • 1Intenal Medicine, Cukurova University Medical Faculty, 01330 - Adana/TR
  • 2Medical Oncology, Adana Numune Education and Research Hospital, 01150 - Adana/TR
  • 3Medical Oncology, Cukurova University Medical Faculty, 01330 - Adana/TR
  • 4Pathology, Cukurova University Medical Faculty, 01330 - Adana/TR


Background and aims

Platin based chemotherapy regimens are most important treatment choices for ovarian carcinoma. Significant numbers of patients develop resistance to platinum combination therapies. We aimed to show the role of ERCC1 expression in the resistance to therapy in ovarian carcinoma.

Patients and methods

Among all patients treated with platinum containing chemotherapy regimens, 27 eligible ovarian cancer patients were selected. Tissue samples were obtained from paraffin blocks and evaluated ERCC1 expression with immunohistochemical method in the pathology department. Expression level 0, 1(+), 2(+) was assessed as low expression, 3(+) was assessed as high expression. The results were correlated with clinical findings and therapy response. Therapy response was assessed for RECIST criteria.


In this study 27 patients with pathologically proven ovarian cancer were enrolled to this study. Sixteen (59%) patients were stage III, and 11(41%) patients were stage IV. Complete response was determined in 18 (67%) patients, stable disease was determined in 3 (11%) patients and progressive disease was determined in 6(22%) patients. Median overall survival was 23 months. Treatment response rates were 50% in high ERCC1 expression group and 90% in low expression group. Statistically significant difference was found between two groups (p = 0.04). The median overall survival was 30 months(95% CI 23-37 months) in low ERCC1 expression group and 15.8 months (95% CI 23-37 months) in high expression group (p = 0.183).


Some primary tumors and most recurrent tumors develop drug resistance that lead to treatment failure. High ERCC1 expression levels are associated with the mechanism of cisplatin resistance in ovarian cancer. ERCC1 expression can be used as a predictive biomarker for the platin containing regimens in ovarian carcinoma.


All authors have declared no conflicts of interest.